Skip to search formSkip to main contentSkip to account menu

IMMU-110

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

DoxorubicinImmunoconjugatesMonoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Doxorubicin conjugates for selective delivery to tumors.
With the aim of improving the therapeutic utility of doxorubicin, numerous conjugates or prodrugshave been prepared to be… 
2006
2006
Anti-CD74-doxorubicin immunoconjugate (IMMU-110) is cytotoxic in non-Hodgkin's lymphoma (NHL) models and overcomes MDR.
7598 Background: The internalizing LL1 anti-CD74 antibody is an optimal agent for delivering drugs, toxins, or radionuclides to… 
2005
2005
Anti-CD 74 Antibody-Doxorubicin Conjugate , IMMU-110 , in a HumanMultipleMyeloma Xenograft and inMonkeys
Purpose: IMMU-110 is a drug immunoconjugate composed of doxorubicin conjugated to the humanized anti-CD74 monoclonal antibody… 
2004
2004
Therapeutic activity of a new antibody-drug immunoconjugate, IMMU-110, in preclinical studies targeted against multiple myeloma.
6535 Background: CD74, a cell-surface-expressed epitope of the HLA class II-associated invariant chain [Ii], is a unique target… 
2004
2004
Therapeutic activity of a new antibody-drug immunoconjugate, IMMU-110, in preclinical studies targeted against multiple myeloma
6535 Background: CD74, a cell-surface-expressed epitope of the HLA class II-associated invariant chain [Ii], is a unique target… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)